2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
76
Polycystic Ovary Syndrome
3
Neoplasms, Hormone-Dependent
3
Neoplasm Metastasis
3
Arthralgia
3
Advanced Breast Cancer
3
Osteoporosis
2
Fractures, Bone
2
Endometrial Neoplasms
2
Carcinoma, Lobular
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Ductal, Breast
2
Breast Diseases
2
Breast Cancer Female
2
Sexuality
1
Sexual Dysfunctions, Psychological
1
Neurotoxicity Syndromes
1
Luminal B/HER2-negative Breast Cancer
1
Leiomyoma
1
Infertility
1
Hot Flashes
1
Hormone-receptor-positive Breast Cancer
1
Hormone Receptor Positive Breast Carcinoma
1
Hormone Receptor Positive Advanced Breast Cancer
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Fatigue
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Interventions
bicalutamide
5
enzalutamide
4
exemestane
2
darolutamide
2
abiraterone
2
pembrolizumab
1
ostarine
1
nilutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Prophylactic Mastectomy
1
Prednisolone
1
Panobinostat
1
Mifepristone
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Docetaxel
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bulbo-Spinal Atrophy, X-Linked
×
Aromatase Inhibitors
×
Clear all
NCT02910050
2017-12-22
BETTER
Sun Yat-sen University
Phase 2
Unknown
58 enrolled